dihydro-alpha-ergocryptine

Dihydro-alpha-ergocryptine is a hydrogenated ergot derivative that functions as a dopamine receptor agonist. It acts primarily as a potent agonist at D2 dopamine receptors and as a partial agonist at D1 and D3 receptors. The drug has a relatively long half-life (12-16 hours) and its absorption is not affected by food intake, providing advantages over levodopa in maintaining consistent dopaminergic stimulation. It has been studied for the treatment of Parkinson's disease, migraine prophylaxis, low blood pressure, and peripheral vascular disorders. In Parkinson's disease, it can be used alone or in combination with levodopa to improve motor symptoms and potentially reduce motor complications. Some evidence suggests it may also have neuroprotective properties.

Brand names

AlmiridCripar

Other names

DihydroergocryptineDihydroergocriptine9,10-dihydro-α-ergocryptinealpha-Dihydroergocriptineα-dihydroergocryptineDihydro a-Ergocryptine